Announcement on License Agreement for the GR1803 Project
Filed with SSE · · 5 pages · Chinese
Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix
Earlier from Chongqing Genrix Biopharmaceutical
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection (Subcutaneous Injection)
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Renewing Engagement of Audit Institution for 2026
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2026 Restricted Stock Incentive Plan
Later from Chongqing Genrix Biopharmaceutical
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
- Announcement on Voluntary Disclosure of the Approval for Market Launch of Siromivimab Injection for Passive Immunization Indication in Adults Exposed to Rabies Virus
- Announcement on Voluntary Disclosure of Withdrawal of Drug Registration Application
- Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Telikibart Injection for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Follow Chongqing Genrix Biopharmaceutical into a list and get an email when it puts out news.
Follow Chongqing Genrix Biopharmaceutical